APYXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Apyx Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.42−0.13 (-5.10%)
Close on Oct 19, 2026
- Market cap
- $106.12M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.50 (−17.12%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Apyx Medical Corp grew revenue 25.6% to $58.42M over the twelve months to Jun 30, 2026. Free cash flow was -$11.05M.
Revenue
$58.42M
+25.6% vs. a year earlier
Operating income
-$3.54M
TTM Q2 2026
Free cash flow
-$11.05M
TTM Q2 2026
EPS, diluted
-$0.20
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $106.12M
- P/E ratio
- –
- Price to sales
- 1.82
- Price to book
- 9.95
- Dividend yield
- –
- Free cash flow yield
- -10.41%
Fundamentals
- Revenue
- $58.42M
- Net income
- -$8.63M
- EPS, diluted
- -$0.20
- Free cash flow
- -$11.05M
- Book value per share
- $0.24
- Diluted shares
- 44M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$58.42M+25.6% YoY
Gross profit
$37.09M+29.4% YoY
Operating income
-$3.54M
Net income
-$8.63M
EPS, diluted
-$0.20
Free cash flow
-$11.05M
Reported periodTrailing twelve months